JAMA Neurol 2022 May 2. Epub 2022 May 2.
Department of Neurology, Epilepsy Program, Hospital Ruber Internacional, Madrid, Spain.
Importance: New treatment options are needed for patients with Lennox-Gastaut syndrome (LGS), a profoundly impairing, treatment-resistant, developmental and epileptic encephalopathy.
Objective: To evaluate the efficacy and safety of fenfluramine in patients with LGS.
Design, Setting, And Participants: This multicenter, double-blind, placebo-controlled, parallel-group randomized clinical trial was conducted from November 27, 2017, to October 25, 2019, and had a 20-week trial duration. Read More